Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite.

Autor: Kisalu NK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Idris AH; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Weidle C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Flores-Garcia Y; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Flynn BJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Sack BK; Seattle Biomedical Research Institute, Seattle, Washington, USA., Murphy S; Seattle Biomedical Research Institute, Seattle, Washington, USA., Schön A; Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA., Freire E; Department of Biology, Johns Hopkins University, Baltimore, Maryland, USA., Francica JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Miller AB; Division of Health Sciences and Technology, Institute for Medical Engineering and Science, and The Broad Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Gregory J; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., March S; Division of Health Sciences and Technology, Institute for Medical Engineering and Science, and The Broad Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Liao HX; Duke Human Vaccine Institute, Durham, North Carolina, USA.; College of Life Science and Technology, Jinan University, Guangzhou, China., Haynes BF; Duke Human Vaccine Institute, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.; Department of Immunology, Duke University Medical Center, Durham, North Carolina, USA., Wiehe K; Duke Human Vaccine Institute, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Trama AM; Duke Human Vaccine Institute, Durham, North Carolina, USA., Saunders KO; Duke Human Vaccine Institute, Durham, North Carolina, USA.; Department of Surgery, Duke University School of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Gladden MA; Duke Human Vaccine Institute, Durham, North Carolina, USA., Monroe A; Duke Human Vaccine Institute, Durham, North Carolina, USA., Bonsignori M; Duke Human Vaccine Institute, Durham, North Carolina, USA.; Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA., Kanekiyo M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Wheatley AK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.; Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., McDermott AB; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Farney SK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Chuang GY; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Zhang B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Kc N; Sanaria Inc., Rockville, Maryland, USA., Chakravarty S; Sanaria Inc., Rockville, Maryland, USA., Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Sinnis P; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Bhatia SN; Division of Health Sciences and Technology, Institute for Medical Engineering and Science, and The Broad Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA., Kappe SHI; Seattle Biomedical Research Institute, Seattle, Washington, USA., Sim BKL; Sanaria Inc., Rockville, Maryland, USA., Hoffman SL; Sanaria Inc., Rockville, Maryland, USA., Zavala F; Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Pancera M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. mpancera@fredhutch.org., Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. rseder@mail.nih.gov.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2019 Jan; Vol. 25 (1), pp. 188-189.
DOI: 10.1038/s41591-018-0315-0
Abstrakt: In the version of this article originally published, data were incorrectly ascribed to monoclonal antibody CIS34 because of a labeling error. The data were generated with monoclonal antibody CIS04. Full details can be found in the correction notice.
Databáze: MEDLINE